► Subscribe to the Financial Times on YouTube: http://bit.ly/FTimeSubs
Once the prey, now the predator, Shire makes its biggest acquisition by buying the US biotechnology company NPS for $5.2bn. Lex's Oliver Ralph and Robert Armstrong discuss the growing risks mid-sized pharmaceutical groups must take.
► Lex: http://bit.ly/1I14JZF
► FT Analysis Review: http://bit.ly/1SrwTzR
For more video content from the Financial Times, visit http://www.FT.com/video